Humana Inc. $HUM Position Boosted by Legal & General Group Plc

Legal & General Group Plc lifted its holdings in Humana Inc. (NYSE:HUM) by 2.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 918,954 shares of the insurance provider’s stock after purchasing an additional 20,126 shares during the period. Legal & General Group Plc’s holdings in Humana were worth $239,084,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. LGT Fund Management Co Ltd. acquired a new stake in Humana during the third quarter valued at approximately $211,000. Schroder Investment Management Group grew its position in Humana by 578.9% in the third quarter. Schroder Investment Management Group now owns 82,969 shares of the insurance provider’s stock worth $21,586,000 after buying an additional 70,748 shares during the last quarter. Inceptionr LLC acquired a new position in Humana in the third quarter worth approximately $646,000. Parallel Advisors LLC increased its holdings in shares of Humana by 51.7% in the third quarter. Parallel Advisors LLC now owns 1,274 shares of the insurance provider’s stock valued at $332,000 after buying an additional 434 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in shares of Humana by 51.1% in the third quarter. Natixis Advisors LLC now owns 55,623 shares of the insurance provider’s stock valued at $14,471,000 after buying an additional 18,818 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider directly owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.37% of the stock is owned by company insiders.

Humana Price Performance

HUM opened at $163.80 on Friday. The firm has a market capitalization of $19.66 billion, a P/E ratio of 16.68, a PEG ratio of 1.75 and a beta of 0.44. The stock has a fifty day moving average of $214.88 and a 200-day moving average of $249.14. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12-month low of $163.60 and a 12-month high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. The firm had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.Humana’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 2.2%. Humana’s dividend payout ratio is currently 36.05%.

Wall Street Analyst Weigh In

HUM has been the subject of several research reports. Wells Fargo & Company reduced their price objective on Humana from $290.00 to $206.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 18th. Guggenheim reduced their target price on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a report on Thursday, February 12th. TD Cowen decreased their price target on Humana from $260.00 to $173.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Cantor Fitzgerald dropped their price target on Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research note on Thursday, February 12th. Finally, Wolfe Research boosted their price objective on Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a report on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $225.48.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.